CDA | Evidence Driven
CDA | Evidence Driven

avatrombopag

Details

Generic Name:
avatrombopag
Project Status:
Pending
Therapeutic Area:
severe thrombocytopenia associated with chronic liver disease (CLD)
Manufacturer:
Sobi Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Doptelet
Project Line:
Reimbursement Review
Project Number:
SR0845-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : May 10, 2024